1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Regular Aspirin Use To Prevent Cardiovascular Events Not Advisable For Most Patients – ACC/AHA Guidelines

 
• By Eileen Francis

Aspirin should be used very selectively in the primary prevention of artherosclerotic cardiovascular disease, according to new guidelines from the American College of Cardiology and American Heart Association. While certain higher-risk adults may benefit from regular, preventative aspirin use, those over the age of 70, and any at increased risk of bleeding, should explore lifestyle changes, the groups say.

Upset senior ill woman holding pill and glass or water taking painkiller medicine to relieve headache pain, sad middle aged elderly lady worried about side effects of meds for old person concept

The American College of Cardiology and the American Heart Association say daily, low-dose aspirin use should be considered “infrequently” as a preventative measure against heart attacks and strokes in adults under 70 without known cardiovascular disease.

Aspirin should not be used for that purpose in the elderly or adults of any age who are at increased...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Cloudy Tariff Conditions Expected To Linger In US

 
• By Malcolm Spicer

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

FDA Takes World Tour In Recent OTC Warnings

 
• By Malcolm Spicer

FDA Center for Drug Evaluation and Research Office of Manufacturing Quality, Office of Compliance and Office of Unapproved Drugs & Labeling Compliance recently advise Indian, Canadian and US firms about GMP problems.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

EU Pharma Reform: Council Proposes Rx Exemption For Topical Antimicrobials

 
• By David Ridley

The EU Council has introduced a key amendment to Article 51 (para 1, point e) of the new pharma directive: “A medicinal product shall be subject to medical prescription where it is an antimicrobial, unless intended for topical use.”

More from Policy & Regulation

Xlear Lawsuit Argues To Shelve FTC Policy For Health Claim Substantiation Under Loper Bright

 
• By Malcolm Spicer

Complaint filed Utah federal court says “Supreme Court explicitly rejected Chevron deference to agency interpretations” in the Loper decision, compelling rejection of “an agency’s statutory interpretation unless the court, ‘after applying all relevant interpretive tools, concludes’ the interpretatio

People On The Move: Appointments At Pharma Deutschland, AMA, FSA

 
• By Tom Gallen

A round-up of the latest people moves: Pharma Deutschland names head of new OTC Market division; the African Medicines Agency appoints director general; the UK's Food Standards Agency adds members to novel foods committee.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By David Ridley

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.